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Summary The benzoaxines have been developed from struc-
turally similar chromones as specific inhibitors of the PI3K
family to sensitize cancer cells to the effects of chemotherapeutic
agents; most have been shown to do this through specific
inhibition of DNA-PK and DNA repair mechanisms. In this
study we examined the benzoxazine, 2-((3-methoxybut-3en-2-
yl)amino)-8methyl-4H-benzo[1,3]oxazin-4one (LTUSI54). This
compound had no DNA-PK or PI3K inhibitory activity but still
sensitized HeLa cells to the effects of Etoposide. LTUSI54
works synergistically with Etoposide to inhibit growth of
HeLa cells and sub G1 analysis indicates that this is not due to
an increase in apoptosis. LTUSI54 neither enhances DSB for-
mation due to Etoposide nor does it delay the repair of such
damage. Cell cycle analysis shows a clear G2 block with
Etoposide alone while, in combination with LTUSI54 there is
an additional S phase arrest. Phospho-kinase analysis indicated
that LTUSI54 engages key regulators of cell cycle progression,
specifically p38α, p53 and ERK 1/2. From our results we
hypothesize that LTUSI54 is promoting the cell cycle arrest
through activation of p38α pathways, independent of p53mech-
anisms. This results in a decrease in p53 phosphorylation and
hence, restricted apoptosis. Changes in cell number appear to be
the result of p38α pathways disrupting cell cycle progression, at
the S and G2 checkpoints. Further investigation into the finer
mechanisms by which LTUSI54 effects cell cycle progression
would be of great interest in assessing this compound as a
chemosensitising agent.
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Introduction
Radiation and some chemotherapeutics, such as Etoposide,
cause double strand DNA breaks (DSB). Etoposide is a
topoisomserase II (topo II) inhibitor. Topo II is an enzyme that
has multiple functions including relaxation of supercoiled DNA,
cell cycle regulation and decatenation of sister chromatids [1, 2].
During the catalytic cycle of topo II, to relax the DNA helix,
topo II creates a transient covalent complex (“cleavable com-
plex”) in the DNA by cleaving the phosphodiester backbone,
essentially creating a DSB for another DNA duplex to pass
through before the DSB is religated [1–3]. In the presence of
topo II inhibitors such as Etoposide, the normally transient
cleavable complex is stabilised resulting in permanent DSBs
[1–3] which are identified by the cell cycle checkpoints. In
eukaryotic cells there are three major checkpoints where the cell
cycle can be blocked due to DNA damage or incomplete repli-
cation; they are necessary for the maintenance of genome integ-
rity and they occur at the transition between G1-S, within S and
at the G2-Mboundary during the cell cycle. Additionally there is
a checkpoint at the exit of mitosis [4, 5]. Activation of cell cycle
checkpoints is initiated by the protein kinase signalling mole-
cules ATM and ATR [4, 6].
Until recently it was thought that checkpoint pathways only
regulated cell cycle transition, however, it is now recognised
that signal transduction cascades link DNA damage signalling,
checkpoints and repair [6, 7]. Once the detection of damage
occurs, the cell cycle is arrested before one of three possible
outcomes is determined; damage can either be repaired in
which case the cell continues to cycle, the cell can enter
senescence and progresses no further or ideally the cell will
be unable to repair the damage and cell death will result by
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apoptosis [8]. Etoposide has been shown to cause DSBs, ATM
activation and apoptosis in all phases of the cell cycle [3].
Increasing the sensitivity of cancer cells to therapy has been
the focus of a number of studies [9–14]. One mechanism that
has been of interest is inhibiting the DNA repair pathways of
cancer cells subsequent to cell cycle arrest and many inhibitors
of these pathways have been developed, some of which are
currently undergoing clinical trials [11–15]. The chromones,
LY294002 and wortmannin, were found to a promising family
of chemo- and radio-sensitisers by inhibition of DNA repair
through inhibition of the PI3K family, including DNA-PK
[16–18]. However, the underlying mechanisms of action have
seldom been specifically elucidated and these inhibitors have
consistently been shown to have broad specificity for other
members of the PI3K family as well as DNA-PK. Hence it is
possible that interactions of these inhibitors with enzymes other
than DNA-PK are a significant contributor, or even an essential
part, of their sensitizing ability. We have developed a series of
benzoxazine analogues of the chromones with a view to in-
creasing their specificity for DNA-PK, while maintaining po-
tency. The compound used in this present study illustrates the
above point in that it has minimal activity against DNA-PK or
PI3K isoforms and yet, it is a potent sensitiser to Etoposide.
In this studywe show that treatment of HeLa, human cervical
cancer, cells with the topo II inhibitor Etoposide can be en-
hanced by the presence of the benzoxazine, 2-((3-methoxybut-
3en-2-yl)amino)-8methyl-4H-benzo[1,3]oxazin-4one
(LTUSI54) (Fig. 1). We show that the increased sensitivity to
Etoposide is independent of DNA repair inhibition or apoptosis
but involves cell cycle arrest.
Materials and methods
Cell lines
HeLa, cervical cancer, cell line used were obtained from the
American Type Culture Collection and was cultured in
Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen,
Grand Island) containing phenol red, supplemented with
10 % foetal bovine serum (FBS, Sigma-Aldrich, St Louis).
Preparation of stock solutions
All stock solutions were diluted using DMSO (Sigma-
Aldrich, St Louis); LTUSI54 was made up to 1 mM (kindly
supplied by Dr. Jasim Al-Rawi and Saleh Ihmaid, La Trobe
University Bendigo, Australia). Etoposide (Sigma-Aldrich, St
Louis) was made up to stocks of 10 mM.
It should be noted that in accordance with Lee et al. [19] the
amount of DMSO added to both test and control media never
exceeded 0.5 % of the total volume, and control cultures were
treated with equivalent volumes of DMSO that was used to
prepare stock solutions of the drug to eliminate adverse effects
of DMSO.
Inhibition assay
The PI3K and DNA-PK inhibition assay was performed by
Reaction Biology Corporation USA. IC50 values greater than




Themethod put forward by Freshney [20] was used to carry out
the assay with slight variations. Cells were seeded on 24 well
plates at a concentration of 2x103cells/well. After cells had
adhered overnight, 1 ml of treatment media was added for
4 h. Treatment media was removed and cells were washed with
0.01 M PBS before 1 ml of recovery media was added to each
well for 48 h. For control cells and Etoposide alone treated cells
recovery media contained media with DMSO only, recovery
media for LTUSI54 alone and Etoposide plus LTUSI54 treated
cells contained 200nMLTUSI54. Absorbance was measured at
538 nm using a Flex Station 3 (Molecular Devices, California).
CellTox™ green cytotoxicity assay
Promega’s CellTox™ cytotoxicity assay was used to investi-
gate the cytotoxic effect of LTUSI54 on HeLa cells. Cells
were seeded in a 96well plate at a concentration of 1x104cells/
well and allowed to adhere overnight. Fifty microlitres of test
media was added to each well containing 0.1 % CellTox green
dye, and incubated for 24 h before plate was read using an
excitation wavelength of 485 nm and emission filter of
520 nm on the Flex Station 3 (Molecular Devices, California).
Flow cytometry for γ-H2AX expression
This assay is essentially as described in MacPhail et al. 2003
[21], cells were seeded at a concentration of 2×105 cells per










Fig. 1 Chemical structure of 2-((3-methoxybut-3en-2-yl)amino)-8meth-
yl-4H-benzo[1,3]oxazin-4one (LTUSI54)
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to adhere overnight. Treatment was with either; 0.5 % DMSO
in DMEM, 25 μM Etoposide alone, 200nM LTUSI54 or the
combination of Etoposide and LTUSI54. Cells were treated
for either 4 h before fixation or alternatively for 4 h in initial
treatment followed by 2 days recovery in recovery media
containing LTUSI54, as outlined in the SRB method.
After treatment, cells were harvested, fixed in 70 % ethanol
at 20 °C overnight before rehydration and staining. Cells were
stained with 100 μL anti H2AX (pSer139) rabbit polyclonal
antibody (Santa Cruz Biotechnology, Santa Cruz, Cat# sc-
101696) diluted 1:500 for 2 h. Following washing, cells were
resuspended in 100 μL goat anti-rabbit IgG (H + L) Alexa
Fluor 488 conjugate (Invitrogen, Grand Island, Cat# A-11008)
diluted 1:200. Finally cells were resuspended in a 5 μg/ml
propidium iodide and analysed on Accuri C6 Flow cytometer
(BD Biosciences, San Jose) and gated to omit doublets.
Cell cycle analysis
Cell cycle and sub G1 analysis was achieved as outlined by
Riccardi and Nicoletti [22]. After treatment, test media was
collected in a centrifuge tube, washed with 0.01 M PBS,
trypsinized and centrifuged at 200 g for 5 min. Cells were
then washed with 0.01 M PBS before being resuspended in
70 % ethanol and stored at −20 °C generally overnight.
Fixed cells were centrifuged at 200 g for 5 min, washed with
0.01 M PBS and resuspended in 250 μL stain solution contain-
ing 25 μg/ml Propidium iodide and 100 μg/ml RNase. Cells
were then incubated at 37 °C in the dark for 30 min before flow
cytometry analysis on the Accuri C6 Flow cytometer (BD
Biosciences, San Jose) and gated to omit doublets and debris.
Human phospho-kinase array
Small flasks of HeLa cells were treated for 4 h with either
media alone, 25 μM Etoposide, 200nM LTUSI54 or a com-
bination of Etoposide and LTUSI54. Following treatment, the
R&D systems Proteome Profiler™ Human Phospho-Kinase
array (R&D Systems, Minneapolis, Cat# ARY003) was used
to analyse protein phosphorylation in each treatment group.
The procedure was carried out as per the manufacturer’s
instructions, cells were lysed using lysis buffer provided and
membranes were incubated overnight in cell lysate at 4 °C to
allow for protein and antibody binding. Protein concentration of
lysate was assayed by the BioRad DC Protein Assay Kit II (Cat
#500-0112, Bio-Rad Laboratories, Philadelphia) and used at
150 μg/ml. Membranes were washed and exposed to the ap-
propriate detection antibody cocktail for 2 h at room tempera-
ture. Again membranes were washed and then exposed to
Streptavidin-HRP for 30 min. After a final wash membranes
were exposed to the prepared Chemi reagent mix for 1 min
before being read at increasing exposures using a Bio-Rad
Chemi Doc station.
Statistics and analysis
Data was graphed using Graph Pad prism 5.0 and presented as
mean ± SEM. Statistical significance was determined using
two-tailed unpaired Students t -test, p values less than 0.05
were taken as statistically significant.
Results
Inhibition assays
LTUSI54 was found to have no inhibitory effect on any of the
PI3K isoforms or DNA-PK. IC50 values greater than 100 μM
were taken as not active (data not shown).
Toxicity of LTUSI54
The SRB assay was used to show changes in cell number in the
presence of LTUSI54 (Fig. 2a). At low concentrations there
was no significant effect of LTUSI54 on HeLa cell number. It
was not until HeLa cells were exposed to 100 μM of LTUSI54
that there was an observed significant increase in cell number
when compared to the control (p =0.0003). Similarly, the
Promega CellTox™ green dye assay results (Fig. 2b) indicated
that LTUSI54 had no cytotoxic effect on HeLa cells at 200nM,
however, as the concentration increased there was an observed
increase in fluoresence indicating an increase in cytotoxicity.
The greatest amount of CellTox fluoresecence was seen at
100 μM LTUSI54, 299.3 RFUs, a significant increase from
the control group, 191 RFUs, generating a p value <0.0001.
Growth inhibition
When HeLa cells were cultured in the presence of Etoposide
alone there was a significant reduction in cell number com-
pared to control (p <0.0001). Similarly, treatment with
LTUSI54 alone resulted in a significant reduction in cell
numbers (p =0.0115). The combination treatment, Etoposide
and LTUSI54, further reduced HeLa cell number (p <0.0001),
enhancing the effect of Etoposide (Fig. 3).
Effect on apoptosis
HeLa cells were culture for 4 h in the various combi-
nations of Etoposide and LTUSI54, and then allowed to
recover for 2 days. The effect on cellular apoptosis was
determined by analysing cells in sub G1 phase (Fig. 4).
After 2 days recovery time, Etoposide treatment caused
a significant increase in apoptotic cells, p <0.0001.
However, the combined treatment with LTUSI54 neither
enhanced nor inhibited this effect. Results showed that
after 4 h treatment there was no significant change in
1468 Invest New Drugs (2013) 31:1466–1475
sub G1 populations regardless of the treatment group
(data not shown).
Flow cytometry for γ-H2AX
γ-H2AX formation was assessed by flow cytometry (Fig. 5).
After 4 h treatment, LTUSI54 alone had no effect on the
number of HeLa cells that stained positive for γ-H2AX
(7.3 % of cells were positive), and thus DSBs. As expected,
treatment with Etoposide increased γ-H2AX expression
(about 80 % of cells positive), and thus caused DSBs.
Combination treatment with Etoposide and LTUSI54 resulted
in no further effect on the number of HeLa cells that stained
positive for γ-H2AX (about 80 %) when compared to
Etoposide alone treated cells.
When HeLa cells were allowed to recover for 2 days, a
reduction in γ-H2AX indicated that cells were able to repair
the DSBs. When HeLa cells were allowed to recover after
treatment with Etoposide there was a decrease in γ-H2AX
expression (only 15 % of cells were positive), suggesting the
majority of samples had DSBs repaired. This repair oc-
curred even in the presence of LTUSI54 (16 % of cells
were positive) suggesting this compound has no effect
on the repair pathways. Treatment of HeLa cells with
LTUSI54 alone had no effect on cells that stained positive
for γ-H2AX (2.7 % of cells were positive). The more than 5
fold decrease in γ-H2AX positive cells, and thus DSBs repair
suggests that Etoposide is causing DSB, but when cells are
allowed to recover, the DNA repair pathways are not inhibited















































Fig. 3 SRB results of HeLa cells treated with 25μMEtoposide both in the
presence and absence of 200nM LTUSI54 for 4 h and allowed to recover
for 2 days in the presence of LTUSI54. Graph indicates mean ± SEM of
four replicates. Statistical significance was determined using two-tailed
t-tests, (asterisk) indicates treatments significantly different to the control
treatment group and (number sign) indicates treatments significantly



































Fig. 4 SubG1 analysis of HeLa cells treated with 25 μMEtoposide both in
the presence and absence of 200nMLTUSI54 for 4 h and allowed to recover
for 2 days in LTUSI54 recovery media. Graph indicates mean ± SEM of
three replicates. Statistical significance was determined using two-tailed
t-tests, (asterisk) indicates treatments significantly different to control
group. (Flow cytometry profiles shown in Fig. 6b)
a b
Fig. 2 Results of HeLa cells treated with varying concentrations of
LTUSI54. a Results of SRB assay after 2 days treatment, graph indicates
mean of 4 replicates ± SEM of four replicates. b Result obtained using the
cell toxicity assay after 24 h treatment, graph indicates mean of eight
replicates ± SEM. Statistical significance was determined using two-tailed
t-tests, (asterisk) indicates results statistically significant to the control
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Cell cycle effects
Cell cycle analysis was used to investigate the effects of treat-
ment on cell cycle progression, results are shown in Fig. 6a.
Exposure to LTUSI54 alone for 4 h caused a significant in-
crease in cells in S phase (p =0.0074) and a corresponding
significant reduction of cells in G2/M phase (p =0.0036).
Etoposide alone treatment also caused an increase in cells in
S phase (p =0.0059) which was further enhanced by the pres-
ence of LTUSI54 (p =0.0006) when compared to Etoposide
alone treatment. This significant S phase block evident in the
combination treatment also resulted in a reduction of cells in
the G2/M phase when compared to Etoposide alone treatment
(p =0.0265).
When cells were allowed to recover for 2 days (Fig. 6b), a
significant reduction in G1 cells was seen with Etoposide and
combination treated cells when compared to control and
LTUSI54 alone treated cells (p <0.0001). There was also a
significant increase in cells in both the S phase for Etoposide
alone (p =0.0016) and the combination treatment (p <0.0001)
when compared to the control group. A reduction of cells in
G2/M phase was seen when cells were exposed to the
LTUSI54 alone (p =0.0417), conversely combination treat-
ment resulted in an increase of cells in this phase (p =
0.0160). However, there was no significant difference in the
number of cells in the G2/M phase between the Etoposide
alone treated cells and the combination treated cells.
Human phospho-kinase array
To determine which proteins are involved in the signalling




Fig. 5 γ-H2AX results obtained for HeLa cells treated with Etoposide in
presence and absence of 200nM LTUSI54. a Flow cytometry results
following 4 h treatment alone with Etoposide, 200nM LTUSI54 alone
and in combination or (b) 4 h treatment followed by 2 days in recovery
media. Left hand gate indicated cells that are considered to have been
negative for γ-H2AX antibody, while right hand gate indicates cells that
were considered to have stained positive for γ-H2AX antibody. c Percent
of cells stained positive for γ-H2AX following 4 h treatment alone and
(d) 4 h treatment followed by 2 days recovery. Graphs indicate mean of
three replicates ± SEM. Statistical significance was determined using
two-tailed T tests. (Asterisk) Indicates treatments significantly different
to control
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after 4 h treatment using the R&D systems proteome profiler
human phospho-kinase array (Fig. 7). Analysis revealed that
cells treated with LTUSI54 alone had a 3.645 fold increase in
the activity of p38α when compared to control levels, this
effect was more significant than Etoposide alone, which only
had a 2.64 fold increase in p38α activity, compared to
control levels. Combination treatment resulted in a 3 fold
increase in the activity of p38α when compared with control.
All three treatment groups showed about a 2 fold increase in
activity of Extracellular signal-regulated protein kinases 1 and
2 (ERK1/2) when compared to the control. The activation of
p53, a key checkpoint protein, was most significantly increased
following treatment with Etoposide (3.5 fold increase). This
increase was somewhat inhibited in the combination treatment
with LTUSI54 showing only 2.35 fold increase when com-
pared to control. LTUSI54 alone also increased the activity of
p53 1.5 fold when compared to the control group, much less
than Etoposide alone treated cells.
Discussion
The benzoaxines have been developed from structurally similar
chromones as specific inhibitors of the PI3K family to sensitize
cancer cells to the effects of chemotherapeutic agents; most
have been shown to do this through specific inhibition of DNA-
PK and DNA repair mechanisms [23, 24]. Structure
activity relationship studies (SAR) have identified key substi-
tutions leading to enhancement of this DNA-PK inhibition,
specifically at position 8 [25]. In this study we examined a
benzoxazine with an alanine substituted at position 2. This






































































































Fig. 6 Cell cycle profiles from flow cytometry analysis of HeLa cells
treated with Etoposide in the presence and absence of LTUSI54 for (a) 4 h
alone and (b) when allowed to recover for 2 days. Percent of cells in each
phase of the cell cycle following (c) 4 h treatment alone and (d) following
2 days recovery time in recovery media containing LTUSI54. Graphs
indicate mean ± SEM of three independent experiments. (Asterisk) Indi-
cates treatments significantly different to control, (number sign) indicates
combination treatments significantly different to Etoposide alone treatment
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activity but still sensitized HeLa cells to the effects of
Etoposide.
The chemotherapeutic effect of Etoposide is characterized
by a reduction in cell number as a result of initiating apoptosis
and mitotic catastrophy following an induction of G2 cell cycle
arrest [26]. Consistent with previous studies [26], treatment of
HeLa cells cells with Etoposide resulted in a significant reduc-
tion in cell number and an increase in apoptosis. In the presence
of LTUSI54, cell numbers were further reduced following
treatment with Etoposide although this was not found to be
due to an increase in apoptosis. However, we did find that
LTUSI54 enhanced the Etoposide induced G2 block.
Consistent with the observation that LTUSI54 had no effect
on the amount of apoptosis induced by Etoposide we also
found no change in the number of DSBs induced by
Etoposide. The phosphorylation of histone H2AX (to γ-
H2AX) following treatment was explored, as an initial signal-
ling event for DNA damage [3, 21, 27–29]. It was evident that
HeLa cells treated with Etoposide resulted in DSBs within the
4 h treatment, consistent with previous studies [3]. When
HeLa cells were allowed 2 days to recover from this damage,
γ-H2AX expression levels had decreased indicating that
DNA repair had taken place. The presence of LTUSI54 during
this recovery time had no effect on the repair of this damage.
The inability of LTUSI54 to inhibit or prolong the repair of
DSBs caused by Etoposide again reinforces the fact that
LTUSI54 has no effect on the activity of DNA-PK or any
other elements involved in DSB damage repair pathways.
The function of many chemotherapy treatments is to cause
sufficient DNA damage that the cell is unable to repair the
damage and goes into apoptosis. In order for this to occur,
mechanisms within the cell must first detect the DNA damage,
institute cell cycle arrest and initiate DNA repair pathways.
Aside from inhibiting DNA repair another mechanism to
enhance the cytotoxic effect of chemotherapy agents is
through disrupting cell cycle progression [5, 30–34]. As the
cell moves through the cell cycle, there are several cell cycle
checkpoints that monitor DNA integrity and inhibit cell cycle
progression if damage is detected. These check points have
been identified between each phase: between G1 and S phase,
S phase and the G2 phase and before cells enter the M phase
[4, 5]. LTUSI54 alone was found to cause cell cycle arrest at
the S checkpoint following initial treatment. In combination,
the arrest of cells in the S phase of the cell cycle induced by
Etoposide was found to be enhanced by the presence of
LTUSI54, which resulted in a corresponding decrease of cells
in the G2/M phase. Following 2 days recovery, LTUSI54
alone treated cells showed a similar cell cycle profile to that
of the control group, with the exception of a decrease of cell in
the G2/M phase. Similarly, combination treatment showed
no significant difference to Etoposide alone treated cells.
This return to normal and no further enhancement of
Etoposide treatment may be due to the stability of LTUSI54
in the cellular environment. LTUSI54 may be broken down
over this period of time eliminating any further effect on the
cell cycle.
These results suggest that the enhanced reduction in cell
numbers seen with the treatment of Etoposide and LTUSI54,
which was found to be independent of an increase in apoptosis
and prolonged DSB repair, is due to early disruption of cell
progression through the cell cycle. In recent years cell cycle
progression has become a major target for improving antican-
cer therapy. The majority of these studies looked at eliminat-
ing the cell cycle checkpoints [5, 30–32] while others have
found benefit in inducing and enhancing cell cycle arrest [33,
34] and many current chemotherapeutic agents elicit their
therapeutic benefit by halting the cell cycle.
To determine the pathway, and possible target molecules
for LTUSI54, the effects on cellular kinases was assessed in
both treated and untreated cells. The kinase array results
indicated a change in phosphorylation levels of three key
kinases, p53, p38α and ERK1/2. p53 is a well-known tumour
suppressor, the protein levels and functional activity of p53
are commonly up-regulated during chemotherapy treatment of
cancers [35]. Treatment with Etoposide resulted in increased
phosphorylation of p53, and increased levels of apoptosis,
suggesting Etoposide is stimulating apoptosis through a p53
dependant mechanisms as has been demonstrated before [3].
In response to DNA damage, activated ATM family kinases
phosphorylate p53 at Ser 15. Phosphorylation at this site
disrupts the interaction of p53 with HDM2 (the human homo-
log of the murine double minute 2 oncogene), leading to the
stabilization of p53 protein [36, 37]. p53 is normally rapidly
degraded by HDM2-mediated ubiquitin-dependent proteoly-
sis [38–40]. p53 has two functional roles, it can induce cell
cycle arrest, through the transactivation of the Cdk inhibitor
p21, or apoptotic cell death through transcription-dependent
and -independent mechanisms [41]. p53 mediated cell cycle
Fig. 7 Example results of Human phospho-kinase of HeLa cells follow-
ing 4 h treatment alone with 25 μM Etoposide, 200nM LTUSI54 or in
combination. Experiment was repeated with both runs containing dupli-
cate antibody spots, a similar trend as shown was observed
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arrest at the transition of cells from G2-M phase involves
upregulation of cell cycle inhibitors such as the CDK inhibitor
p21, GADD45a (growth arrest and DNA-damage-inducible
45 alpha) as well as 14-3-3 sigma proteins [42]. These factors
all play a key role for cells to progress through the G2/M
checkpoint of the cell cycle by inhibiting the activation of
Cdc2/Cyclin B complex by Cdc25that is needed for entry into
mitosis, hence resulting in a G2 arrest [40, 43].
p53 mediated apoptosis occurs through the intrinsic path-
way, which is regulated by the pro- and anti-apoptotic Bcl-2
family of proteins that directly affect mitochondrial outer-
membrane permeabilization (MOMP) [38, 39]. The two main
Bcl-2 family members that influence p53 mediated MOMP
are Bax and Bak. Oligomerization of these proteins occurs by
the direct or indirect activation of Bcl-2-homology domain-3
(BH3)-only pro-apoptotic Bcl-2 family members [38, 39, 44].
Bax and Bak p53-induced activation triggers the release of
mitochondrial cytochrome c and APAF which activate the
caspase cascade of apoptosis leading to cell death [38, 39].
Combination treatment of Etoposide with LTUSI54, showed
an inhibitory effect on p53 phosphorylation when compared to
Etoposide alone treated cells. However, LTUSI54 alone only
showed a 1.5 fold increased in p53 phosphorylation much less
than Etoposide, with no corresponding increase in apoptosis,
suggesting that LTUSI54 has a positive effect on the p53 depen-
dent role in cell cycle arrest rather than apoptosis.
In response to DSBs, such as those caused by Etoposide,
activation of p38α occurs and leads to the establishment of a
G2/M cell cycle arrest [45]. p38α is a member of the mitogen
activated protein kinases (MAPK) [45], it is a stress activated
protein kinase that inhibits cell cycle progression at both the
G1/S and the G2/M checkpoints [46]. Treatment of HeLa cells
with LTUSI54 alone showed a much greater increase in p38α
phosphorylation than Etoposide alone treatment when
compared to the control group (3.645 and 2.64 fold increase
respectively). Treatment with Etoposide alone resulted in
phosphorylation of p38α and cell cycle arrest at the G2/M
checkpoint, consistent with the role of p38α in G2/M cell
cycle arrest [40, 47]. DNA damage is detected by ATM and
ATR kinases, ATM indirectly phosphorylate p38α via activa-
tion of the Thousand and one (Tao) kinases [45]. Once acti-
vated p38α can induce cell cycle arrest via 2 pathways, one
involving p53 as previously described, the other through
activation of MAPK activated kinase 2 (MK2) [40, 43].
MK2 in turn phosphorylates Cdc25B and Cdc25C, which
induces their binding to 14-3-3 proteins, resulting in the
prevention of Cdc25 activating the Cdc2/Cyclin B complex
that is needed for entry into mitosis [40, 43]. Similarly, MK2
activation has previously been found to initiate the S phase
checkpoint via phosphorylation-dependent depletion of
Cdc25A [40], which could explain to the observed increase
in cells in the S phase following LTUSI54 treatment.
HeLa cells treated with LTUSI54 alone, resulted in a sig-
nificantly higher p38α phosphorylation but lower p53 activa-
tion, compared to Etoposide alone treatment. This can be
attributed to the actions of p38α and MK2 in destabilizing
p53. Initially, activation of both p38α and MK2 stabilises and
activates p53, however activation of MK2 also leads to the
phosphorylation of HDM2 [48]. Activation of HDM2 leads to
a reduction in p53 stability and may play a role in moderating
the extent and duration of a stress induced p53 response.
Previous studies have shown that phosphorylation of
HDM2 at Ser 157 and 166 reduces the stabilisation of p53
and promotes its degradation [48].
Consistent with previous studies treatment of HeLa cells
with Etoposide resulted in increased ERK1/2 expression.
ERK1/2 has been found to play a role in the progression
through the cell cycle, mainly the transition of cells from G1
Fig. 8 Proposed mechanism
of action for Etoposide and
LTUSI54. LTUSI54 appears to
promote the MK2 dependent
(p53 independent) pathway of cell
cycle arrest over p53 dependent
mechanisms. As MK2 is
phosphorylated, it phosphorylates
HDM2, which destabilises p53,
inhibiting the p53 mediated
apoptosis pathways
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phase into S phase [49]. ERK1/2 is phosphorylated down-
stream of MEKs in the RAF-MEK-ERK1/2 pathway, it pro-
motes G1 progression by interactions with D-type cyclins,
Cdk4, stabilisation of c-Myc, regulation of p21 and p27 as
well as down regulating anti-proliferative genes such as Tob1,
Ddit3 and JunD [49–51]. All three treatment groups up regu-
lated ERK1/2 indicating that they all activate the RAF-MEK-
ERK pathway, as the main role for ERK phosphorylation is
understood to be the progression of cells through G1 into S
phase, it is no surprise that the observed results showed no
arrest of cells in the G1 phase.
From our results we hypothesize that LTUSI54 is promoting
the MK2 pathway of cell cycle arrest over that of p53 depen-
dent mechanisms (summarised in Fig. 8). However, as the
phosphorylation of p53 increased in the presence of LTUSI54
it appears that the p53 dependent pathway of cell cycle arrest is
still activated. As the MK2 pathway is up regulated, phosphor-
ylation of HDM2 occurs at Ser 157 and 166, promoting deg-
radation of p53 [48]. Such degradation of p53 would account
for the reduction in p53 expression levels observed when
LTUSI54 was present in combination with Etoposide when
compared to the Etoposide alone treated HeLa cells.
Similarly, p53 mediated apoptosis would be effected by the
presence of LTUSI54 and its corresponding HDM2 phosphor-
ylation. This would account for the lack of increased apoptosis
observed when LTUSI54 was present in combination with
Etoposide. LTUSI54 could possibly be promoting the MK2
dependent pathway of cell cycle arrest and hence p53 degra-
dation by activating proteins downstream of p38α. Possible
targets for LTUSI54 include p38α itself, MK2 or even HDM2,
possibly at the Ser 157 and 166 sites that promote the degra-
dation of p53 and reduce p53 dependent apoptotic pathways.
LTUSI54 is a novel compound which has been found to
enhance the cytotoxic effects of Etoposide on the HeLa cervi-
cal cancer cell line. This response is independent of increased
apoptosis and appears to be the result of disrupted cell cycle
progression, at the S and G2 checkpoints. Further in-
vestigation into the finer mechanisms by which LTUSI54 up
regulates the p53 independent cell cycle arrest, including its
effects on MK2 and HDM2, would be of great interest in
assessing this compound as a chemosensitising agent.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
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